Latest from Lennox-Gastaut Syndrome Foundation

The investigational therapy met its primary end point, showing superiority to placebo in reducing the frequency of drop seizures in patients with Lennox-Gastaut syndrome.
The section chief of pediatric neurology at Nationwide Children’s Hospital discusses the realities parents face when exploring CBD to treat epilepsy.
Zogenix has announced that its Study 1601 of fenfluramine (Fintepla), also known as ZX008, in the treatment of seizures associated with Lennox-Gastaut syndrome has completed enrollment and is on schedule to report top-line data in Q1 2020.
The impact of Dravet and Lennox-Gastaut syndrome on patients and caregivers.
Expert neurologists consider the diagnostic tools available to accurately determine a patient’s status for Dravet and Lennox-Gastaut Syndrome.
Key opinion leaders discuss how to avoid misdiagnosing Lennox-Gastaut syndrome and enumerate the various types of associated seizures.
The section chief of pediatric neurology at Nationwide Children’s Hospital and an associate professor of clinical pediatrics and neurology at The Ohio State University College of Medicine spoke about what the findings mean for patients.
SAP Partner Banner